Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.70
Bid: 6.60
Ask: 6.70
Change: 0.00 (0.00%)
Spread: 0.10 (1.52%)
Open: 6.75
High: 6.90
Low: 6.55
Yest. Close: 6.80
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Nuformix PLC - Loan Conversion

Fri, 24th May 2019 07:00

RNS Number : 1024A
Nuformix PLC
24 May 2019
 

 

Nuformix plc

("Nuformix" or the "Company")

 

Conversion of Loan Note

 

Cambridge, UK, 16 May 2019: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that it has received notice from Mr Alan Miller in accordance with the Convertible Loan Agreement dated 18 April 2017 (as amended) to convert the outstanding loan of £200,000 with accrued interest ("Loan"). In accordance with the notice the Company has today issued 8,716,512 ordinary shares fully paid and 8,716,512 warrants to subscribe for ordinary shares at 2.75p per share exercisable at any time for 60 months to Mr Miller in settlement of the Loan.

 

Enquiries:

 

Nuformix plc

Dr Dan Gooding, Chief Executive Officer

Tel: +44 (0)1223 423667

 

About Nuformix plc  www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

 

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs.  Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

 

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. 

 

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CONFMGZKKDMGLZG
Date   Source Headline
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:36 pmRNSPrice Monitoring Extension
25th Nov 20197:00 amRNSUpdate and Placing Announcement
28th Oct 20192:05 pmRNSSecond Price Monitoring Extn
28th Oct 20192:00 pmRNSPrice Monitoring Extension

Login to your account

Don't have an account? Click here to register.